Pegylation of poly(γ-benzyl-L-glutamate) nanoparticles is efficient for avoiding mononuclear phagocyte system capture in rats

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 1103-1111

  Özcan, Ipek ^a   Segura Sánchez, Freimar ^b,c   Bouchemal, Kawthar ^b   Sezak, Murat ^a   Özer, Özgen ^a   Güneri, Tamer ^a   Ponchel, Gilles ^b  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Biodistribution; Nanoparticles; PBLG; Pegylation; Physicochemical characterization

Indexed keywords

BOVINE SERUM ALBUMIN; FLUORESCEIN ISOTHIOCYANATE; MACROGOL; NANOCARRIER; NANOPARTICLE; POLY(GAMMA BENZYL GLUTAMATE); POLY(GAMMA BENZYL GLUTAMATE)BENZYLAMINE; POLY(GAMMA BENZYL GLUTAMATE)FLUORESCEIN ISOTHIOCYANATE; POLY(GAMMA BENZYL GLUTAMATE)POLYETHYLENE GLYCOL; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MACROGOL DERIVATIVE; POLY GAMMA BENZYL GLUTAMATE; POLY-GAMMA-BENZYL-L-GLUTAMATE; POLYGLUTAMIC ACID;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; MOLECULAR IMAGING; MONONUCLEAR PHAGOCYTE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; ZETA POTENTIAL; ANALYSIS OF VARIANCE; ANIMAL; CATTLE; CHEMISTRY; DRUG DELIVERY SYSTEM; LIVER; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHAGOCYTOSIS; SPLEEN; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY;

BOVINAE; RATTUS;

ANALYSIS OF VARIANCE; ANIMALS; CATTLE; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MOLECULAR WEIGHT; NANOPARTICLES; PARTICLE SIZE; PHAGOCYTOSIS; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; RATS; SERUM ALBUMIN, BOVINE; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 79954468694     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S15493     Document Type: Article

References (45)

1. Jeong YI, Seo SJ, Park IK, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(γ -benzyl-L-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm. 2005;296:151-161.
2. Martinez-Barbosa ME, Bouteiller L, Cammas-Marion S, Montembault V, Fontaine L, Ponchel G. Synthesis and ITC characterization of novel nanoparticles constituted by poly(γ -benzyl L-glutamate)-β-cyclodextrin. J Mol Recognit. 2008;21:169-178.
3. Zhu Z, Li Y, Li X, et al. Paclitaxel-loaded poly(N-vinylpyrrolidone)- b-poly(e-caprolactone) nanoparticles: preparation and antitumor activity in vivo. J Control Release. 2010;142:438-446.
4. Wang LY, Wang SG, Bei JZ. Synthesis and characterization of macroinitiator-amino terminated PEG and poly(γ-benzyl-Lglutamate)-PEO- poly(γ-benzyl-L-glutamate) triblock copolymer. Polym Adv Technol. 2004;15:617-621.
5. Cheon JB, Jeong YI, Cho CS. Effects of temperature on diblock copolymer micelle composed of poly(γ-benzyl L-glutamate) and poly(Nisopropylacrylamide). Polymer. 2006;40:2041-2050.
6. Qi L, Xu Z. In vivo antitumor activity of chitosan nanoparticles. Bioorg Med Chem Lett. 2006;16:4243-4245.
7. Geze A, Chau LT, Choisnard L, et al. Biodistribution of intravenously administered amphiphilic β-cyclodextrin nanospheres. Int J Pharm. 2007;344: 135-142
8. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1-9.
9. Nanjwade BK, Singh J, Parikh KA, Manvi FV. Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles. Int J Pharm. 2010;385:176-180.
10. Cheng J, Teply BA, Sherifi I, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomater. 2007;28:869-876.
11. Govender T, Riley T, Ehtezazi T, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000;199:95-110.
12. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm. 2007;336:367-375.
13. Sepassi S, Goodwin DJ, Drake AF, et al. Effect of polymer molecular weight on the production of drug nanoparticles. J Pharm Sci. 2007;96:2655-2666.
14. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003;42:463-478.
15. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93-102.
16. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010;141:320-327.
17. Avgoustakis K, Beletsi A, Panagi Z, et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003; 259:115-127.
18. Yang T, Cui FD, Choi MK, et al. Enhanced solubility and stability of pegylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 2007;338:317-326.
19. Park J, Fong PM, Lu J, et al. Pegylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine. 2009;5:410-418.
20. Bhadra D, Bhadra S, Jain P, Jain NK. Pegnology: a review of PEGylated systems. Pharmazie. 2002;57:5-29.
21. Veronese FM, Pasut G. Pegylation, successful approach for drug delivery. Drug Discov Today. 2005;10:1451-1458.
22. Diaz-Lopez R, Tsapis N, Santin M, et al. The performance of pegylated nanocapsules of perfluorooctyl bromide as an ultrasound contrast agent. Biomater. 2010;31:1723-1731.
23. Gref R, Domb A, Quellec P, et al. The controlled intravenous delivery of drugs using PEG coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16:215-233.
24. Zhen XL, Kan B, Gou ML, et al. Preparation of mPEG-PLA nanoparticle for honokiol delivery in vitro. Int J Pharm. 2010;386:262-267.
25. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-co- glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Release. 2001;70:353-363.
26. Zambaux MF, Faivre-Fiorina B, Bonneaux F, et al. Involvement of neutrophilic granulocytes in the uptake of biodegradable non-stealth and stealth nanoparticles in guinea pig. Biomaterials. 2000;21:975-980.
27. Martinez-Barbosa ME, Montembault V, Cammas-Marion S, Ponchel G, Fontaine L. Synthesis and characterization of novel poly(γ-benzyl-Lglutamate) derivatives tailored for the preparation of nanoparticles of pharmaceutical interest. Polym Int. 2007;56:317-324.
28. Martinez-Barbosa ME, Cammas-Marion S, Bouteiller L, Vauthier C, Ponchel G. Pegylated degradable composite nanoparticles based on mixtures of PEG-b-poly(γ-benzyl L-glutamate) and poly(γ-benzyl L-glutamate). Bioconjugate Chem. 2009;20:1490-1496.
29. Segura-Sánchez F, Montembault V, Fontaine L, Martínez-Barbosa E, Bouchemal K, Ponchel G. Synthesis and characterization of functionalized poly(γ-benzyl-L-glutamate) derivates and corresponding nanoparticles preparation and characterization. Int J Pharm. 2010; 387:244-252.
30. Ozcan I, Segura-Sánchez F, Bouchemal K, et al. Effects of sterilization techniques on the PEGylated poly(γ-benzyl-L-glutamate) (PBLG) nanoparticles. Acta Pharm Sciencia. 2009;51:211-218.
31. Dawson B, Trapp RG. Basic and Clinical Biostatistics. USA: McGraw Hill; 2001:161-182.
32. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86:33-48.
33. Song X, Zhao Y, Wu W, et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm. 2008;350:320-329.
34. Huang MJ, Gou ML, Qian ZY, et al. One-step preparation of poly(epsiloncaprolactone)- poly(ethylene glycol)-poly(epsiloncaprolactone) nanoparticles for plasmid DNA delivery. J Biomed Mater Res A. 2008;86:979-986.
35. Wang D, Miller S, Sima M, Kopeckova P, Kopecek J. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjugate Chem. 2003;14:853-859.
36. Peracchia MT, Fattal E, Desmaele D, et al. Stealth pegylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release. 1999;60:121-128.
37. Vila A, Gill H, McCallion O, Alonso MJ. Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Release. 2004;98:231-244.
38. Kim TH, Park TG. Critical effect of freezing/freeze-drying on sustained release of FITC-dextran encapsulated within PLGA microspheres. Int J Pharm. 2004;271:207-214.
39. Pygall SR, Whetstone J, Timmins P, Melia CD. Pharmaceutical applications of confocal laser scanning microscopy: The physical characterisation of pharmaceutical systems. Adv Drug Del Rev. 2007;59: 1434-1452.
40. Zhao J, Wu J. Preparation and characterization of the fluorescent chitosan nanoparticle probe. Chinese J Anal Chem. 2006;34:1555-1559.
41. Guo G, Liu W, Liang J, Xu H, He Z, Yang X. Preparation and characterization of novel CdSe quantum dots modified with poly (D, L-lactide) nanoparticles. Mater Lett. 2006;60:2565-2568.
42. Suh J, Choy KL, Lai SK, et al. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomed. 2007;2:735-741.
43. Stolnik S, Heald CR, Neal J, et al. Polylactide-poly(ethylene glycol) micellar-like particles as potential drug carriers: production, colloidal properties and biological performance. J Drug Target. 2001;9: 361-378.
44. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm. 2005;298:233-241.
45. Sonavane G, Tomoda K, Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids Surf B Biointerfaces. 2008;66:274-280.